Effectiveness of successive booster vaccine doses against SARS-CoV-2 related mortality in residents of Long-Term Care Facilities in the VIVALDI study

This research has not been peer-reviewed. It is a preliminary report that should not be regarded as conclusive, guide clinical practice or health-related behaviour, or be reported in news media as established information.

We evaluated the effectiveness of 1-3 booster vaccinations against SARS-CoV-2 related mortality among a cohort of 13407 older residents of long-term care facilities (LTCFs) participating in the VIVALDI study in England in 2022. Cox regression was used to estimate relative hazards of SARS-CoV-2 related death following booster vaccination relative to 2 doses (after 84+ days), stratified by previous SARS-CoV-2 infection and adjusting for age, sex and LTCF capacity. Each booster provided additional short-term protection relative to primary vaccination, with consistent pattern of waning to 45-75% reduction in risk beyond 112 days.

Author list

 

Affiliations:

  1. University College London
  2. UK Health Security Agency
  3. University of Birmingham

Authors:

Oliver Stirrup1, Madhumita Shrotri1, Natalie L. Adams1, Maria Krutikov1, Borscha Azmi1, Igor Monakhov2, Gokhan Tut3, Paul Moss3, Andrew Hayward1, Andrew Copas1 and Laura Shallcross1

 

Novel Coronavirus SARS-CoV-2

10.1101/2023.03.01.23286627

MedRxiv

Read full preprint